New approaches to target inflammation in atherosclerosis remain elusive, as a potential first-in-class drug fails in two mega trials.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Mullard, A. GSK's darapladib failures dim hopes for anti-inflammatory heart drugs. Nat Rev Drug Discov 13, 481–482 (2014). https://doi.org/10.1038/nrd4381
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4381
This article is cited by
-
Lp-PLA2 inhibition prevents Ang II-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation
Acta Pharmacologica Sinica (2021)